SCHEMBL5028660

SCHEMBL5028660

Cc1cc(N2CCCC2)c2ccc(NCCc3ccccc3Cl)cc2n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCF1 P14598 7/20 0.51
ADRB2 P07550 1/20 0.41
ADRB1 P08588 1/20 0.41
LMNA P02545 3/20 0.41
HTT P42858 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
USP2 O75604 2/20 0.41
MAPK1 P28482 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
TSHR P16473 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
PKM P14618 1/20 0.40
HSD17B10 Q99714 1/20 0.40
NPY5R Q15761 1/20 0.40
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5022538 0.90 NCF1 (0.53) NCF1ADRB2ADRB1LMNAHTT
SCHEMBL6709246 0.83 MRGPRX1 (0.47) NCF1LMNAHTTSMN1; SMN2USP2
SCHEMBL5028620 0.81 NCF1 (0.55) NCF1ADRB2ADRB1LMNAHTT
SCHEMBL5025398 0.79 NCF1 (0.56) NCF1ADRB2ADRB1LMNAHTT
SCHEMBL5026888 0.79 NCF1 (0.50) NCF1ADRB2ADRB1MEN1KMT2A
SCHEMBL5022706 0.78 NCF1 (0.51) NCF1ADRB2ADRB1MEN1KMT2A
SCHEMBL5024510 0.78 KDM4E (0.56) NCF1LMNAHTTSMN1; SMN2USP2
SCHEMBL5040484 0.77 NCF1 (0.53) NCF1ADRB2ADRB1LMNAHTT
SCHEMBL5024407 0.77 NCF1 (0.50) NCF1ADRB2ADRB1LMNAHTT
SCHEMBL5026871 0.77 NPC1 (0.52) NCF1LMNAHTTSMN1; SMN2USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1474145-B1 QUINOLINE DERIVATIVES AS NPY ANTAGONISTS HOFFMANN LA ROCHE (CH) 2008-04-23 EP disclosed
CN-1627945-A Quinoline derivatives as NPY antagonists HOFFMANN LA ROCHE (CH) 2005-06-15 CN disclosed
EP-1474145-A1 QUINOLINE DERIVATIVES AS NPY ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-11-10 EP disclosed
US-6696467-B2 Quinoline derivatives HOFFMANN-LA ROCHE INC. 2004-02-24 US disclosed
WO-2003066055-A1 QUINOLINE DERIVATIVES AS NPY ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2003-08-14 WO disclosed
US-20030153553-A1 Quinoline derivatives F. HOFFMANN-LA ROCHE AG (CH) 2003-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030153553-A1 Quinoline derivatives NPY1R, NPY4R, GLP1R NCF1 1858/4885ADRB2 519/4885ADRB1 141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.